US10519212B2ActiveUtilityA1

Long-acting recombinant follicle-stimulating hormone and use thereof

Assignee: GUANGZHOU VBIO PHARMA CO LTDPriority: Nov 1, 2013Filed: Aug 22, 2014Granted: Dec 31, 2019
Est. expiryNov 1, 2033(~7.3 yrs left)· nominal 20-yr term from priority
A61P 5/06A61P 15/00A61K 38/00C07K 2319/00C07K 14/59C07K 2319/75C07K 2319/30C12N 15/79C12N 2800/60
32
PatentIndex Score
0
Cited by
10
References
1
Claims

Abstract

Disclosed in the present invention is a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (referred to as hFSH-Fc for short) and a preparation method thereof, wherein the hFSH-Fc protein is a dimerized fusion protein and the amino acid sequence thereof successively comprises an hFSHβ subunit, CTP, an hFSHα subunit, a flexible peptide linker and human IgG2 Fc variant from N-terminal to C-terminal. Also disclosed in the present invention is the use of the recombinant hFSH-Fc fusion protein composition in preparing drugs in the animal breeding field.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method for animal breeding in a subject thereof, comprising administering a recombinant homodimeric hFSH-Fc fusion protein to the subject, wherein the recombinant homodimeric hFSH-Fc fusion protein with an amino acid sequence sequentially comprising an hFSH β-subunit, CTP, hFSH α-subunit, a flexible peptide linker, and human IgG2 Fc variant, from N-terminal to C-terminal,
 wherein said human IgG2 Fc variant comprises a hinge with a Pro331Ser mutation, CH2, and CH3 domains; and 
 wherein the amino acid sequence of the fusion protein is set forth in SEQ ID NO:2.

Join the waitlist — get patent alerts

Track US10519212B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.